TISIDB

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane; Lipid-anchor, GPI-anchor.
Domain	PF02872 5'-nucleotidase PF00149 Calcineurin-like phosphoesterase
Function	Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.

> Gene Ontology [ TOP ]
Biological Process	GO:0006152 purine nucleoside catabolic process GO:0006195 purine nucleotide catabolic process GO:0006196 AMP catabolic process GO:0006213 pyrimidine nucleoside metabolic process GO:0007159 leukocyte cell-cell adhesion GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009125 nucleoside monophosphate catabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009128 purine nucleoside monophosphate catabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009154 purine ribonucleotide catabolic process GO:0009158 ribonucleoside monophosphate catabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009163 nucleoside biosynthetic process GO:0009164 nucleoside catabolic process GO:0009166 nucleotide catabolic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009169 purine ribonucleoside monophosphate catabolic process GO:0009261 ribonucleotide catabolic process GO:0016311 dephosphorylation GO:0019439 aromatic compound catabolic process GO:0031348 negative regulation of defense response GO:0032102 negative regulation of response to external stimulus GO:0034655 nucleobase-containing compound catabolic process GO:0042278 purine nucleoside metabolic process GO:0042451 purine nucleoside biosynthetic process GO:0042454 ribonucleoside catabolic process GO:0042455 ribonucleoside biosynthetic process GO:0044270 cellular nitrogen compound catabolic process GO:0046033 AMP metabolic process GO:0046085 adenosine metabolic process GO:0046086 adenosine biosynthetic process GO:0046128 purine ribonucleoside metabolic process GO:0046129 purine ribonucleoside biosynthetic process GO:0046130 purine ribonucleoside catabolic process GO:0046135 pyrimidine nucleoside catabolic process GO:0046434 organophosphate catabolic process GO:0046700 heterocycle catabolic process GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0072522 purine-containing compound biosynthetic process GO:0072523 purine-containing compound catabolic process GO:0072527 pyrimidine-containing compound metabolic process GO:0072529 pyrimidine-containing compound catabolic process GO:1901136 carbohydrate derivative catabolic process GO:1901292 nucleoside phosphate catabolic process GO:1901361 organic cyclic compound catabolic process GO:1901565 organonitrogen compound catabolic process GO:1901657 glycosyl compound metabolic process GO:1901658 glycosyl compound catabolic process GO:1901659 glycosyl compound biosynthetic process
Molecular Function	GO:0008252 nucleotidase activity GO:0008253 5'-nucleotidase activity GO:0016791 phosphatase activity GO:0042578 phosphoric ester hydrolase activity
Cellular Component	GO:0031225 anchored component of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00230 Purine metabolism hsa00240 Pyrimidine metabolism hsa00760 Nicotinate and nicotinamide metabolism hsa01100 Metabolic pathways
Reactome	R-HSA-1430728: Metabolism R-HSA-15869: Metabolism of nucleotides R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-196849: Metabolism of water-soluble vitamins and cofactors R-HSA-196807: Nicotinate metabolism R-HSA-74259: Purine catabolism R-HSA-73847: Purine metabolism R-HSA-73621: Pyrimidine catabolism R-HSA-73848: Pyrimidine metabolism

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NT5E and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NT5E and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27245613	Cervical Carcinoma	Inhibit immunity	PKA also stimulated the binding of the coactivator p300 to HIF-1α to enhance its transcriptional activity and counteracted the inhibitory effect of asparaginyl hydroxylation on the association of p300 with HIF-1α. Furthermore, increased cAMP concentrations enhanced the expression of HIF target genes encoding CD39 and CD73, which are enzymes that convert extracellular adenosine 5'-triphosphate to adenosine, a molecule that enhances tumor immunosuppression and reduces heart rate and contractility.
26363007	Ovarian Carcinoma	Inhibit immunity (T cell function)	Furthermore, high levels of CD73 expression in ovarian tumor cells abolished the good prognosis associated with intraepithelial CD8(+) cells.
25403716	Melanoma	Inhibit immunity (T cell function)	The generation of adenosine via the CD39/CD73 pathway is recognized as a major mechanism of regulatory T cell (Treg) immunosuppressive function. Blockade of CD39 increases CTL- and NK cell–mediated killing.
29375567	Ovarian Carcinoma	Inhibit immunity	Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Metformin triggered activation of AMP-activated protein kinase α (AMPKα) and subsequently suppressed hypoxia-inducible factor-α (HIF-1α), which was critical for induction of CD39/CD73 expression in MDSC.
29374065	Ovarian Carcinoma	Inhibit immunity (T cell function); immunotherapy target	Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. Furthermore, metformin treatment correlated with longer overall survival in diabetic patients with ovarian cancer, which was accompanied by a metformin-induced reduction in the frequency of circulating CD39+CD73+ MDSC and a concomitant increase in the antitumor activities of circulating CD8+ T cells. Our results highlight a direct effect of metformin on MDSC and suggest that metformin may yield clinical benefit through improvement of antitumor T-cell immunity by dampening CD39/CD73-dependent MDSC immunosuppression in ovarian cancer patients.
27321181	Ovarian carcinoma	Inhibit immunity	Adenosine is a major determinant of the immunosuppressive tumor milieu. Sequential hydrolysis of extracellular ATP catalyzed by CD39 and CD73 is the main pathway for the generation of adenosine in the tumor interstitium. Preclinical data show that targeting the adenosine-generating pathway (that is, CD73) or adenosinergic receptors (that is, A2A) relieves immunosuppresion and potently inhibits tumor growth.\
21292811	Colon Carcinoma; Lymphoma; Breast Carcinoma; Melanoma	Inhibit immunity (T cell function)	We found that CD73 ablation significantly suppressed the growth of ovalbumin-expressing MC38 colon cancer, EG7 lymphoma, AT-3 mammary tumors, and B16F10 melanoma. The protective effect of CD73 deficiency on primary tumors was dependent on CD8(+) T cells and associated with an increased frequency of antigen-specific CD8(+) T cells in peripheral blood and tumors and increased antigen-specific IFN-γ production.
23776241	Triple-Negative Breast Carcinoma	Inhibit immunity; immunotherapy target	Using mouse models of breast cancer, we demonstrated that CD73 overexpression in tumor cells conferred chemoresistance to doxorubicin, a commonly used anthracycline, by suppressing adaptive antitumor immune responses via activation of A2A adenosine receptors. Targeted blockade of CD73 enhanced doxorubicin-mediated antitumor immune responses and significantly prolonged the survival of mice with established metastatic breast cancer. Taken together, our data suggest that CD73 constitutes a therapeutic target in TNBC.
23737488	Malignant Glioma	Inhibit immunity (T cell function)	We demonstrated that increased suppression of responder CD4(+) T-cell proliferation suppression was induced by CD4(+)CD39(+) T cells in the presence of CD73(+) glioma cells, which could be alleviated by the CD39 inhibitor ARL67156, the CD73 inhibitor APCP, or the adenosine receptor A2aR antagonist SCH58261. Our data indicate that glioma-derived CD73 contributes to local adenosine-mediated immunosuppression in synergy with CD39 from infiltrating CD4(+)CD39(+) T lymphocytes, which could become a potential therapeutic target for treatment of malignant glioma and other immunosuppressive diseases.
22396496	Fibrosarcoma; Prostate Carcinoma; Metastatic Malignant Neoplasm in the Lung	Inhibit immunity (T and NK cell function); immunotherapy target	CD73 deficiency suppressed the development of 3-methylcholanthrene (MCA)-induced fibrosarcomas through a mechanism relying upon IFN-γ, natural killer (NK) cells, and CD8(+) T cells. Importantly, treatment with an anti-CD73 monoclonal antibody effectively suppressed growth of established MCA-induced tumors or TRAMP-C1 prostate tumors and inhibited the development of TRAMP-C1 lung metastases.
29663369	Squamous Cell Carcinoma	Inhibit immunity (T cell function); immunotherapy target	Altogether, these findings highlight the immunoregulatory role of CD73 in the development of HNSCC and we propose that CD73 may prove to be a promising immunotherapeutic target for the treatment of HNSCC.
29574275	Malignant Ovarian Neoplasm	Inhibit immunity (T cell function); immunotherapy target	In order to further enhance the therapeutic efficacy, anti-CD73 and anti-OX40 immunostimulants were combined with mCTH-ANXA5, resulting in an increase of survival by 100% from 12 to 24 days post-therapy and decrease tumor burden in mice with orthotopic metastatic ovarian cancer.
23964122	B16 Malignant Melanoma	Inhibit immunity	CD73 inhibits antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets. CD73 also enhances tumor metastasis, although the nature of the immune subsets and adenosine receptor subtypes involved in this process are largely unknown.
20080644	Breast Carcinoma	Inhibit immunity	Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.In addition to its immunosuppressive effect, CD73 enhanced tumor-cell chemotaxis, suggesting a role for CD73-derived adenosine in tumor metastasis. In conclusion, our study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis.
29145561	Triple-Negative Breast Carcinoma	Inhibit immunity	CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Our results demonstrated that high levels of CD73 expression on epithelial tumor cells were significantly associated with reduced disease-free survival, overall survival and negatively correlated with tumor immune infiltration (Spearman's R= -0.50, p < 0.0001).
28652246	Melanoma	Inhibit immunity; Resistant to immunotherapy	Here we found that induction of CD73, the enzyme that generates immunosuppressive adenosine, is linked to melanoma phenotype switching. We also detected CD73 upregulation in melanoma patients progressing under adoptive T-cell transfer or immune checkpoint blockade, arguing for an adaptive resistance mechanism.
27993599	Breast Carcinoma	Inhibit immunity; Resistant to immunotherapy	Our results showed that intravenous administration of CD73-specific siRNA-loaded NPs led to reduced expression of CD73 in tumor cells which was associated with decreased tumor growth and metastasis, and improved mice survival. In conclusion, our findings indicate that the use of CD73-specific siRNA-loaded NPs provides an immune potentiating function, thereby improves the efficacy of DC based cancer immunotherapy.
22826317	Melanoma	Inhibit immunity (T cell function)	Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. CD73 is a cell surface enzyme that suppresses T cell-mediated immune responses by producing extracellular adenosine. In this study, we demonstrate that administration of a specific CD73 inhibitor, adenosine 5'-(α,β-methylene)diphosphate (APCP), to melanoma-bearing mice induced a significant tumor regression by promoting the release of Th1- and Th17-associated cytokines in the tumor microenvironment.
20179192	Ovarian Carcinoma	Inhibit immunity	CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Because the ecto-5'-nucleotidase activity of CD73 catalyzes AMP breakdown to immunosuppressive adenosine, we hypothesized that CD73-generated adenosine prevents tumor destruction by inhibiting antitumor immunity. We confirmed this hypothesis by showing that combining tumor CD73 knockdown and tumor-specific T-cell transfer cured all tumor-bearing mice.
25205101	melanoma	Inhibit immunity	However, current protocols for ex vivo programming of Th17 cells, which include TGFbeta exposure, increase the expression of CD39 and CD73, two cell surface ATP ectonucleotidases that reduce T-cell effector functions and promote immunosuppression

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NT5E in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NT5E in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.991	0.226
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.964	0.623
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-1.007	0.503
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.363	0.388
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.441	0.788
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.264	0.897
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.133	0.84
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.037	0.98
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.206	0.907
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.194	0.901
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.524	0.459
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.636	0.00139

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NT5E in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	0	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	0	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NT5E. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NT5E. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NT5E. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NT5E. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NT5E expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NT5E and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NT5E
Name	5'-nucleotidase, ecto (CD73)
Aliases	CD73; eN; eNT; CALJA; 5' nucleotidase (CD73); E5NT; Purine 5-Prime-Nucleotidase; CD antigen CD73
Chromosomal Location	6q14-q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NT5E collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting NT5E.

ID	Name	Drug Type	Targets	#Targets
DB00806	Pentoxifylline	Small Molecule	ADORA1, ADORA2A, NT5E, PDE4A, PDE4B, PDE5A	6

Browse NT5E